selodenoson
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 18, 2002 (NCT00040001)
Timeline
2000s
- Jan 1, 2002
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Adenosine A1 receptorAGONIST
ADORA1 agonist
Chemistry & pharmacology
Loading structure…
SMILES
CCNC(=O)[C@H]1O[C@@H](n2cnc3c(NC4CCCC4)ncnc32)[C@H](O)[C@@H]1O- Mol. weight
- 376.42 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2107371 ↗
Also known as
- dti0009
- dti 0009
- dti-0009
- dti-0009
- dti-0009
- gr-56072
- gr-56072
- n-5'-ethyl-n(6)-(cyclpentyl)adenosine-5'-uronamide
- rg14202
- rg 14202
- rg-14202
- rg-14202
- rg-14202
- selodenoson
- selodenoson
- selodenoson
- selodenoson
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00040001 | Phase 2 | Jun 18, 2002 | Aderis |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aderis | For profit | 1 | 1 | 1 | 2002 |
1 organizations
Page 1 / 1